Tariff Pause Reinforces Uncertainty Among Biopharma Professionals

As Pharmaceutical Technology® Group was busy networking with industry leaders at INTERPHEX 2025 in New York City on April 2, United States President Donald Trump scheduled the announcement of what he called “Liberation Day” with a 10% baseline tariff on imported goods from most other countries in the world, effective April 5 (1).

One week later, in the early morning hours of April 9, Trump went ahead with levying reciprocal taxes on countries the president had felt engaged in unfair trading practices, according to an Associated Press report (1). Those tariffs were what, later that day, Trump then selected for a 90-day pause that briefly sent a boomerang through US and worldwide stock markets, which were sent reeling.

With news breaking in the middle of the three-day INTERPHEX conference, a prompt posed by PharmTech Group to several of its interviewees at the conference ran the risk of becoming quickly obsolete: If this may apply to your company, give us your thoughts on the current tariffs being enacted by the US and the reshoring expectations relative to this change in policy, and how you believe this may impact you or the industry.

While some of the interview subjects politely declined the question, several attacked it head-on and laid out their companies’ plans for both the short and long term.

Click the video above to view a compilation of those responses.

Click here for complete coverage of INTERPHEX 2025.

Reference

1. Wiseman, P. and Rugaber, C. Another U-Turn: Trump Reverses Tariffs That Caused Market Meltdown, But Companies Remain Bewildered. APNews.com, April 10, 2025.